Mirum Pharmaceuticals delivered a two-part catalyst in fibrodysplasia ossificans progressiva and chronic hepatitis delta virus. The company reported FDA approval for its once-daily oral ALK2 inhibitor Atebrioz (zilurgisertib), then followed with Phase 3 data for brelovitug showing achievement of the primary virologic response and ALT normalization endpoints in chronic hepatitis delta, reinforcing Mirum’s commercial positioning in a market dominated by Gilead’s footprint.